■多巴胺-2受体激动剂,溴隐亭和卡麦角林,最初被引入用于泌乳素瘤,垂体瘤,和帕金森病,但有降糖作用。本文系统综述了多巴胺2受体激动剂对糖化血红蛋白(HbA1c)和空腹血糖(FBS)的影响,并进行了全面系统的检索,以确定多巴胺2受体激动剂对糖化血红蛋白(HbA1c)和空腹血糖(FBS)的相关临床试验。
■我们在数据库中进行了系统的综述搜索(PubMed,谷歌学者,科克伦图书馆,寄存器,和引文),直到2022年11月30日,使用PRISMA2020声明。牛津质量评分(Jadad评分)用于评估研究质量。本研究方案在PROSPERO数据库上注册,ID:CRD42023389582。该研究包括完整摘要的研究,预定剂量,明确的干预措施,和血糖测量。
■数据来自招募6125名研究对象的23项临床研究。临床试验的汇总效应分析显示,多巴胺2激动剂改善了HbA1c[SMD=-1.26;95%CI(-1.60,-0.93),P<.00001],和FBS[SMD=-1.84;95%CI(-2.61,-1.07),P<.00001].每种药物的混合效应分析表明溴隐亭显着改善了HbA1c[SMD=-1.25;95%CI(-1.64,-0.87),P<.00001]和FBS[SMD=-1.90;95%CI(-2.79,-1.01),P<.00001]和类似的,卡麦角林显着改善HbA1c[SMD=-1.29;95%CI(-1.96,-0.62),P<.00001]和FBS[SMD=-1.62;95%CI(-2.82,-0.41),P<.00001].汇总和单独的分析表明,多巴胺2激动剂在临床研究中具有降低血糖水平的显着能力。
■这项研究表明,多巴胺2激动剂显着降低了FBS和HbA1c的水平,而不会引起严重的负面影响。即使结果很有希望,额外的研究是必要的,以建立适当的抗高血糖剂量,日常使用的频率,副作用,和潜在的产物相互作用时,使用多巴胺2受体激动剂的抗高血糖作用。
UNASSIGNED: The Dopamine-2 receptor agonists, Bromocriptine and Cabergoline, were originally introduced for prolactinomas, pituitary tumors, and parkinson\'s disease but have glucose-lowering effects. This paper systematically reviewed the significance of their effects on lowering blood glucose level and conducted a comprehensive systematic search to identify relevant clinical trials of dopamine 2 agonists on glycated hemoglobin (HbA1c) and fasting blood sugar (
FBS).
UNASSIGNED: We conducted a systematic review search in the databases (PubMed, Google Scholar, Cochrane Library, Registers, and Citations) until November 30, 2022, using the PRISMA 2020 statement. The Oxford quality score (Jadad score) was used to assess the study\'s quality. The present study protocol was registered on the PROSPERO database with ID: CRD42023389582. The study included studies with full abstracts, predefined doses, clear interventions, and blood glucose measurements.
UNASSIGNED: Data were synthesized from 23 clinical studies that recruited 6125 study subjects. The pooled effect analysis of the clinical trials revealed that dopamine 2 agonists improved HbA1c [SMD = -1.26; 95% CI (-1.60, -0.93), P < .00001], and
FBS [SMD = -1.84; 95% CI (-2.61, -1.07), P < .00001]. Each drug\'s pooled effect analysis indicates bromocriptine significantly improved HbA1c [SMD = -1.25; 95% CI (-1.64, -0.87), P < .00001] and
FBS [SMD = -1.90; 95% CI (-2.79, -1.01), P < .00001] and similarly, cabergoline significantly improved HbA1c [SMD = -1.29; 95% CI (-1.96, -0.62), P < .00001] and
FBS [SMD = -1.62; 95% CI (-2.82, -0.41), P < .00001]. The pooled and individual analyses demonstrated that dopamine 2 agonists have a significant ability to lower blood glucose levels in clinical studies.
UNASSIGNED: This study shows that dopamine 2 agonists significantly lowered
FBS and HbA1c levels without causing severe negative effects. Even though the results are promising, additional research is necessary to establish the appropriate antihyperglycemic dosage, frequency of daily use, side effects, and potential product interactions when employing dopamine 2 receptor agonists for their antihyperglycemic effect.